EA202191833A1 - Композиции и способы применения 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида - Google Patents
Композиции и способы применения 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамидаInfo
- Publication number
- EA202191833A1 EA202191833A1 EA202191833A EA202191833A EA202191833A1 EA 202191833 A1 EA202191833 A1 EA 202191833A1 EA 202191833 A EA202191833 A EA 202191833A EA 202191833 A EA202191833 A EA 202191833A EA 202191833 A1 EA202191833 A1 EA 202191833A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- difluoroacetamide
- dioxopiperidin
- oxoisoindolin
- chlorophenyl
- methyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
В данном документе предложены составы и способы применения 2-(4-хлорфенил)-N-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида или его стереоизомера или смеси стереоизомеров, фармацевтически приемлемой соли, таутомера, пролекарства, изотополога, сольвата, гидрата, сокристалла, клатрата или полиморфа.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862787034P | 2018-12-31 | 2018-12-31 | |
PCT/US2019/068924 WO2020142422A1 (en) | 2018-12-31 | 2019-12-30 | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5yl) methyl)-2,2-difluoroacetamide |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202191833A1 true EA202191833A1 (ru) | 2021-10-11 |
Family
ID=71121614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202191833A EA202191833A1 (ru) | 2018-12-31 | 2019-12-30 | Композиции и способы применения 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида |
Country Status (13)
Country | Link |
---|---|
US (1) | US20200206212A1 (ru) |
EP (1) | EP3906030A4 (ru) |
JP (1) | JP2022515670A (ru) |
KR (1) | KR20210110616A (ru) |
CN (1) | CN113347974A (ru) |
AU (1) | AU2019418587A1 (ru) |
BR (1) | BR112021012578A2 (ru) |
CA (1) | CA3125189A1 (ru) |
EA (1) | EA202191833A1 (ru) |
IL (1) | IL284509A (ru) |
MX (1) | MX2021007800A (ru) |
SG (1) | SG11202106598QA (ru) |
WO (1) | WO2020142422A1 (ru) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10052315B2 (en) | 2016-01-08 | 2018-08-21 | Celgene Corporation | Formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
JP2023505254A (ja) | 2019-12-06 | 2023-02-08 | セルジーン コーポレーション | 2-(4-クロロフェニル)-n-((2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-イル)メチル)-2,2-ジフルオロアセトアミドを製造するための方法 |
MX2023001401A (es) * | 2020-08-03 | 2023-05-03 | Captor Therapeutics S A | Degradadores de proteinas de bajo peso molecular y sus aplicaciones. |
WO2024040154A2 (en) * | 2022-08-17 | 2024-02-22 | The Regents Of The University Of California | Inhalable compositions of cdk9 inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9499514B2 (en) * | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
US10052315B2 (en) * | 2016-01-08 | 2018-08-21 | Celgene Corporation | Formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
CN109414436A (zh) * | 2016-06-06 | 2019-03-01 | 细胞基因公司 | 用2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺治疗血液恶性肿瘤 |
-
2019
- 2019-12-30 CN CN201980090422.3A patent/CN113347974A/zh active Pending
- 2019-12-30 CA CA3125189A patent/CA3125189A1/en active Pending
- 2019-12-30 BR BR112021012578-7A patent/BR112021012578A2/pt unknown
- 2019-12-30 MX MX2021007800A patent/MX2021007800A/es unknown
- 2019-12-30 KR KR1020217022620A patent/KR20210110616A/ko unknown
- 2019-12-30 US US16/730,591 patent/US20200206212A1/en not_active Abandoned
- 2019-12-30 JP JP2021538284A patent/JP2022515670A/ja active Pending
- 2019-12-30 AU AU2019418587A patent/AU2019418587A1/en not_active Abandoned
- 2019-12-30 EP EP19907888.2A patent/EP3906030A4/en active Pending
- 2019-12-30 EA EA202191833A patent/EA202191833A1/ru unknown
- 2019-12-30 SG SG11202106598QA patent/SG11202106598QA/en unknown
- 2019-12-30 WO PCT/US2019/068924 patent/WO2020142422A1/en unknown
-
2021
- 2021-06-30 IL IL284509A patent/IL284509A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210110616A (ko) | 2021-09-08 |
BR112021012578A2 (pt) | 2021-09-08 |
CN113347974A (zh) | 2021-09-03 |
US20200206212A1 (en) | 2020-07-02 |
MX2021007800A (es) | 2021-10-26 |
IL284509A (en) | 2021-08-31 |
EP3906030A1 (en) | 2021-11-10 |
JP2022515670A (ja) | 2022-02-21 |
SG11202106598QA (en) | 2021-07-29 |
WO2020142422A1 (en) | 2020-07-09 |
EP3906030A4 (en) | 2022-09-07 |
CA3125189A1 (en) | 2020-07-09 |
AU2019418587A1 (en) | 2021-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019003857A1 (es) | Composiciones y métodos de uso de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida solicitudes relacionadas. | |
EA202191833A1 (ru) | Композиции и способы применения 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида | |
EA201891578A1 (ru) | Композиции 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил-2,2-дифторацетамида | |
UY38297A (es) | Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos | |
ECSP20001149A (es) | Compuestos antiproliferativos y métodos para utilizarlos | |
AR108711A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
JOP20190229B1 (ar) | مركبات تثبط بروتين mcl-1 | |
EA202192029A1 (ru) | Замещенные производные 3-(1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и варианты их применения | |
CR20190124A (es) | Inhibidores de ssao de aminopirimidina | |
EA201691302A1 (ru) | Новые гетероциклические соединения | |
EA201992299A1 (ru) | Соединения на основе ингибиторов ask1 и их применение | |
EA202091893A1 (ru) | Новые кристаллические формы | |
CY1121746T1 (el) | Αναστολεις mgat2 τετραζολονο-υποκατεστημενης διυδροπυριδινονης | |
EA201692268A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
EA201892746A1 (ru) | Лечение гематологической злокачественной опухоли с помощью 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида | |
EA201991700A1 (ru) | Селективные ингибиторы jak1 | |
EA201791327A1 (ru) | Композиции 2-(трет-бутиламино)-4-((1r,3r,4r)-3-гидрокси-4-метилциклогексиламино)пиримидин-5-карбоксамида | |
CL2017001479A1 (es) | Combinación farmacéutica que comprende un agonista selectivo del receptor s1p1 | |
EA202091279A1 (ru) | Полиморфы и твердые формы пиримидиниламино-пиразолового соединения и способы их получения | |
BR112017012547A2 (pt) | Composições de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h- indazol-5-il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il) fenil)-3,6-diidropiridin-1(2h)-il)-2-oxoetil)-3-(metiltio) pirrolidina-3-carboxamida para preparações farmacêuticas | |
EA202090176A1 (ru) | Композиции и способы применения 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида | |
CO2018002545A2 (es) | Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona | |
EA202191904A1 (ru) | Фармацевтические композиции, содержащие (s)-4-(4-(4-(((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-4-ил)окси)метил)бензил)пиперазин-1-ил)-3-фторбензонитрил и способы их применения | |
BR112017012558A2 (pt) | Composições de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h- indazol-5-il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il) fenil)-3,6-diidropiridin-1(2h)-il)-2-oxoetil)-3-(metiltio) pirrolidina-3-carboxamida para preparações farmacêuticas | |
BR112022008647A2 (pt) | Composto de imidazolidinona, método de preparação do mesmo e uso do mesmo |